Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Decitabine* / pharmacology
  • Decitabine* / therapeutic use
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / mortality
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Sulfonamides* / therapeutic use
  • Treatment Outcome

Substances

  • venetoclax
  • Decitabine
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides